GSK's mRNA flu vaccine candidate advancing to Phase III is a positive pipeline catalyst, but revenue impact is years away. Monitor Phase III enrollment and interim data readouts. The Fast Track designation may accelerate regulatory review. Competitors include Moderna and Pfizer/BioNTech in the mRNA flu space.
GSK drugs
GSK drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $50.66entry
- T+1 · 3mo ago −0.43%α −0.88% · $50.44
- T+5 · 2mo ago −4.01%α −4.09% · $48.63
- T+20 · 7w ago −3.93%α −5.11% · $48.67
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GSK announced positive Phase II data for its mRNA seasonal flu vaccine candidate (FLUm3HA.b-3NA), showing higher immune responses vs. standard and high-dose vaccines in younger and older adults. The candidate targets both HA and NA antigens, a novel approach for mRNA flu vaccines. GSK will initiate a Phase III efficacy trial in September 2026, and the FDA granted Fast Track designation in July 2026. This is a positive pipeline catalyst but remains early-stage with no near-term revenue impact.
Key Facts
- Phase II data showed higher immune responses vs. standard and high-dose flu vaccines in younger and older adults.
- GSK intends to start a Phase III efficacy trial in September 2026.
- FDA granted Fast Track designation in July 2026.
- Vaccine candidate targets both haemagglutinin (HA) and neuraminidase (NA) antigens.
- This will be the first Phase III trial of an mRNA flu vaccine designed to target both HA and NA.
- The vaccine candidate is not approved anywhere in the world.
Financial Impact
No financial figures disclosed. Pipeline milestone with potential future revenue if approved; Phase III trial costs are R&D expense.
Risk Factors
- Phase III trial may fail to meet efficacy or safety endpoints.
- mRNA flu vaccine market is competitive with Moderna and Pfizer/BioNTech advancing similar candidates.
- Regulatory approval and commercial launch are several years away.
- Vaccine not yet approved anywhere; no guarantee of eventual approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007998 |
| Document: 0001654954-26-007998-index-headers.html | 0001654954-26-007998 |
| Document: 0001654954-26-007998-index.html | 0001654954-26-007998 |
| Document: 0001654954-26-007998.txt | 0001654954-26-007998 |
Track record
64 reports on GSK
9 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +9.35% at T+60 after the Jul 17, 2026 report. 15 of 20 went positive at some point.
Filters
- Nov 13, 20263d ago 6-K Neutral 4/10 Entry $50.45 Now $50.41 −0.08% settles Dec 14
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $50.64 Now $50.41 −0.45% settles Dec 11
- Nov 6, 202610d ago 6-K Neutral 1/10 Entry $50.33 Now $50.41 +0.16% settles Dec 7
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $49.13 Now $50.41 +2.61% settles Dec 1
- Oct 28, 202619d ago 6-K Neutral 5/10 Entry $48.74 Now $50.41 +3.43% settles Nov 25
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 1/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 26, 202621d ago 6-K Neutral 4/10 Entry $51.10 Now $50.41 −1.35% settles Nov 23
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $50.02 Now $50.41 +0.78% settles Nov 18
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers